Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1

Neuro-Oncology

Volumn 14, Issue 10, 2012, Pages 1227-1238

  Chou, Chii Wen ^a,b,c   Wang, Chi Chung ^f   Wu, Chung Pu ^d   Lin, Yu Jung ^e   Lee, Yu Chun ^e   Cheng, Ya Wen ^a   Hsieh, Chia Hung ^e  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

ABCB1; cycling hypoxia; glioblastoma; hypoxia inducible factor 1; multidrug resistance (MDR) 1

Indexed keywords

CARMUSTINE; DOXORUBICIN; HOE 33342; HYPOXIA INDUCIBLE FACTOR 1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; FLUORESCENCE ACTIVATED CELL SORTING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOFLUORESCENCE TEST; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CYCLING HYPOXIA; TUMOR MICROENVIRONMENT;

ANIMALS; ANOXIA; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUCIFERASES; MALE; MICE; MICE, INBRED NOD; MICE, SCID; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866920135     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos195     Document Type: Article

References (46)

1. Sulman EP, Guerrero M, Aldape K. Beyond grade: molecular pathology of malignant gliomas. Semin Radiat Oncol. 2009;19(3): 142-149.
2. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006;1: 97-117.
3. Salgaller ML, Liau LM. Current status of clinical trials for glioblastoma. Rev Recent Clin Trials. 2006;1(3): 265-281.
4. Minniti G, Muni R, Lanzetta G, Marchetti P, Enrici RM. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009;29(12): 5171-5184.
5. Lu C, Shervington A. Chemoresistance in gliomas. Mol Cell Biochem. 2008;312(1-2): 71-80.
6. Sarkaria JN, Kitange GJ, James CD, et al. Mechanisms of chemoresist-ance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14(10): 2900-2908.
7. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem. 2008;8(7): 790-797.
8. Coleman CN. Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. J Natl Cancer Inst. 1988;80(5): 310-317.
9. Martinive P, Defresne F, Bouzin C, et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res. 2006;66(24): 11736-11744.
10. Frederiksen LJ, Siemens DR, Heaton JP, Maxwell LR, Adams MA, Graham CH. Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. J Urol. 2003;170(3): 1003-1007.
11. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev. 1994;13(2): 139-168.
12. Wartenberg M, Ling FC, Muschen M, et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 2003;17(3): 503-505.
13. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the mul-tidrug resistance (MDR1) gene. Cancer Res. 2002;62(12): 3387-3394.
14. Bourhis J, Goldstein LJ, Riou G, Pastan I, Gottesman MM, Benard J. Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res. 1989;49(18): 5062-5065.
15. Demeule M, Shedid D, Beaulieu E, et al. Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int J Cancer. 2001;93(1): 62-66.
16. Valera ET, Lucio-Eterovic AK, Neder L, et al. Quantitative PCR analysis of the expression profile of genes related to multiple drug resistance in tumors of the central nervous system. J Neurooncol. 2007;85(1): 1-10.
17. Leweke F, Damian MS, Schindler C, Schachenmayr W. Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohisto-chemical demonstration of P-glycoprotein. Pathol Res Pract. 1998; 194(3): 149-155.
18. Hsieh CH, Lee CH, Liang JA, Yu CY, Shyu WC. Cycling hypoxia increases U87 glioma cell radioresistance via ROS induced higher and long-term HIF-1 signal transduction activity. Oncol Rep. 2010; 24(6): 1629-1636.
19. Hsieh CH, Kuo JW, Lee YJ, Chang CW, Gelovani JG, Liu RS. Construction of mutant TKGFP for real-time imaging of temporal dynamics of HIF-1 signal transduction activity mediated by hypoxia and reoxygenation in tumors in living mice. J Nucl Med. 2009; 50(12): 2049-2057.
20. Serganova I, Doubrovin M, Vider J, et al. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res. 2004;64(17): 6101-6108.
21. Szulc J, Aebischer P. Conditional gene expression and knockdown using lentivirus vectors encoding shRNA. Methods Mol Biol. 2008; 434: 291-309.
22. Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an orthotopic xe-nograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res. 2006;12(7 Pt 1): 2264-2271.
23. Decleves X, Amiel A, Delattre JY, Scherrmann JM. Role of ABC transporters in the chemoresistance of human gliomas. Curr Cancer Drug Targets. 2006;6(5): 433-445.
24. Ziegler DS, Kung AL, Kieran MW. Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol. 2008;26(3): 493-500.
25. Shain KH, Dalton WS. Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert Rev Hematol. 2009;2(6): 649-662.
26. Sanna K, Rofstad EK. Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer. 1994;58(2): 258-262.
27. Sutherland RM, Eddy HA, Bareham B, Reich K, Vanantwerp D. Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys. 1979;5(8): 1225-1230.
28. Ludwig C. Drug resistance of hypoxic tumour cells in vitro. Cancer Treat Rev. 1984;11(Suppl A): 173-178.
29. Wilson RE, Keng PC, Sutherland RM. Drug resistance in Chinese hamster ovary cells during recovery from severe hypoxia. J Natl Cancer Inst. 1989;81(16): 1235-1240.
30. Haensgen G, Krause U, Becker A, et al.Tumorhypoxia, p53, andprognosis in cervical cancers. Int J Radiat Oncol Biol Phys. 2001;50(4): 865-872.
31. Saito Y, Milross CG, Hittelman WN, et al. Effect of radiation and pacli-taxel on p53 expression in murine tumors sensitive or resistant to apo-ptosis induction. Int J Radiat Oncol Biol Phys. 1997;38(3): 623-631.
32. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6(8): 583-592.
33. Dewhirst MW. Relationships between cycling hypoxia, HIF-1, angiogen-esis and oxidative stress. Radiat Res. 2009;172(6): 653-665.
34. Suzuki T, Maruno M, Wada K, et al. Genetic analysis of human glioblas-tomas using a genomic microarray system. Brain Tumor Pathol. 2004;21(1): 27-34.
35. Chan HS, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med. 1991;325(23): 1608-1614.
36. Wu CP, Hsieh CH, Wu YS. The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy. Mol Pharm. 2011;8(6): 1996-2011.
37. Chen L, Feng P, Li S, et al. Effect of hypoxia-inducible factor-1alpha silencing on the sensitivity of human brain glioma cells to doxorubicin and etoposide. Neurochem Res. 2009;34(5): 984-990.
38. Liu L, Ning X, Sun L, et al. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 2008;99(1): 121-128.
39. Fang Y, Sullivan R, Graham CH. Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity. Exp Cell Res. 2007;313(5): 867-877.
40. Riganti C, Doublier S, Viarisio D, et al. Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression. Br J Pharmacol. 2009;156(7): 1054-1066.
41. Lau CK, Yang ZF, Lam SP, et al. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer Biol Ther. 2007;6(12): 1900-1907.
42. Li L, Lin X, Shoemaker AR, Albert DH, Fesik SW, Shen Y. Hypoxia-inducible factor-1 inhibition in combination with temozolo-mide treatment exhibits robust antitumor efficacy in vivo. Clin Cancer Res. 2006;12(15): 4747-4754.
43. Durmaz R, Deliorman S, Uyar R, Isiksoy S, Erol K, Tel E. The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme. Clin Neurol Neurosurg. 1999;101(4): 238-244.
44. Rittierodt M, Tschernig T, Harada K. Modulation of multidrug-resistance- associated P-glycoprotein in human U-87 MG and HUV-ECC cells with antisense oligodeoxynucleotides to MDR1 mRNA. Pathobiology. 2004;71(3): 123-128.
45. Friebe A, Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol. 1998;53(1): 123-127.
46. Hung CC, Liou HH. YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway. Invest New Drugs. 2011;29(6): 1337-1346.